 |
|
Selective Estrogen Receptor Modulators and Prevention of Invasive Breast Cancer
William J. Gradishar, MD;
David Cella, PhD
JAMA. 2006;295:2784-2786. Published online June 5, 2006 (doi:10.1001/jama.295.23.jed60037).
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
This year, more than 200 000 women in the United States will be diagnosed as having invasive breast cancer.1 The past 20 years of research translating an understanding of basic biology into therapeutics has led to major improvements in the survival and quality of life of patients who carry a diagnosis of breast cancer. Parallel strategies to prevent breast cancer have also been studied. These include lifestyle modification (eg, diet, alcohol intake, optimizing weight, exposure to exogenous estrogens), ablative surgery (prophylactic mastectomy, oophorectomy, or both), and more recently, chemoprevention with selective estrogen receptor modulators (SERMs) such as tamoxifen.
More than 30 years ago, tamoxifen entered clinical trials and demonstrated significant antitumor activity in patients with advanced breast cancer. Understanding of what characterized the type of patient and the types of tumors that would benefit from tamoxifen was refined with an understanding of estrogen receptor . . . [Full Text of this Article]
Author Affiliation: Division of Hematology/Oncology and Lynn Sage Breast Cancer Program, Northwestern University Feinberg School of Medicine (Dr Gradishar); and Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Dr Cella), Chicago, Ill.
RELATED ARTICLES
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Victor G. Vogel, Joseph P. Costantino, D. Lawrence Wickerham, Walter M. Cronin, Reena S. Cecchini, James N. Atkins, Therese B. Bevers, Louis Fehrenbacher, Eduardo R. Pajon, Jr, James L. Wade, III, André Robidoux, Richard G. Margolese, Joan James, Scott M. Lippman, Carolyn D. Runowicz, Patricia A. Ganz, Steven E. Reis, Worta McCaskill-Stevens, Leslie G. Ford, V. Craig Jordan, Norman Wolmark, and for the National Surgical Adjuvant Breast and Bowel Project (NSABP)
JAMA. 2006;295(23):2727-2741.
ABSTRACT
| FULL TEXT
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Stephanie R. Land, D. Lawrence Wickerham, Joseph P. Costantino, Marcie W. Ritter, Victor G. Vogel, Myoungkeun Lee, Eduardo R. Pajon, James L. Wade, III, Shaker Dakhil, James B. Lockhart, Jr, Norman Wolmark, and Patricia A. Ganz
JAMA. 2006;295(23):2742-2751.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A New Small Molecule Inhibitor of Estrogen Receptor {alpha} Binding to Estrogen Response Elements Blocks Estrogen-dependent Growth of Cancer Cells
Mao et al.
J. Biol. Chem. 2008;283:12819-12830.
ABSTRACT
| FULL TEXT
Raloxifene vs Tamoxifen
Goldstein
JAMA 2007;297:263-264.
FULL TEXT
International Union of Pharmacology. LXIV. Estrogen Receptors
Dahlman-Wright et al.
Pharmacol. Rev. 2006;58:773-781.
FULL TEXT
Raloxifene vs. Tamoxifen: Breast Cancer and Other Outcomes in the STAR Trial
JWatch Women's Health 2006;2006:2-2.
FULL TEXT
Raloxifene vs. Tamoxifen in Reducing Risk for Invasive Breast Cancer
JWatch General 2006;2006:1-1.
FULL TEXT
|
